Several other equities research analysts have also commented on ACHN. Svb Leerink lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating and boosted their price objective for the stock from $5.00 to $6.30 in a research report on Friday, October 18th. ValuEngine upgraded shares of Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, October 16th. JMP Securities lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating in a research report on Thursday, November 7th. Finally, Leerink Swann lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating and set a $6.30 price objective on the stock. in a research report on Friday, October 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $4.96.
Shares of NASDAQ ACHN opened at $6.19 on Friday. The firm has a market capitalization of $866.91 million, a P/E ratio of -11.46 and a beta of 1.59. Achillion Pharmaceuticals has a one year low of $2.06 and a one year high of $6.46. The company’s fifty day moving average is $6.15 and its two-hundred day moving average is $4.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.96 and a current ratio of 8.96.
In related news, Director David Scheer sold 10,485 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $6.31, for a total value of $66,160.35. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $252,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.58% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Achillion Pharmaceuticals by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,257,553 shares of the biopharmaceutical company’s stock valued at $32,851,000 after purchasing an additional 324,147 shares during the last quarter. UBS Group AG grew its holdings in shares of Achillion Pharmaceuticals by 48.6% during the 2nd quarter. UBS Group AG now owns 5,575,528 shares of the biopharmaceutical company’s stock worth $14,942,000 after purchasing an additional 1,824,534 shares during the period. Millennium Management LLC grew its holdings in shares of Achillion Pharmaceuticals by 38,088.2% during the 3rd quarter. Millennium Management LLC now owns 3,287,622 shares of the biopharmaceutical company’s stock worth $11,835,000 after purchasing an additional 3,279,013 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Achillion Pharmaceuticals by 31.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,007,000 shares of the biopharmaceutical company’s stock worth $8,059,000 after purchasing an additional 728,000 shares during the period. Finally, Nuveen Asset Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the 2nd quarter worth about $7,805,000. 79.81% of the stock is owned by hedge funds and other institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Further Reading: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.